3-Oxoolean-12-en-27-oic acid inhibits the proliferation of non-small cell lung carcinoma cells by inducing cell-cycle arrest at G0/G 1 phase

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2179-2185

  Tae, Nara ^a   Seo, Juhee ^a   Min, Byung Sun ^b   Ryoo, Sungwoo ^a   Lee, Jeong Hyung ^a  

^a Kangwon National University   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

3 Oxoolean 12 en 27 oic acid; Cell cycle arrest; Lung cancer cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 OXOOLEAN 12 EN 27 OIC ACID; ANTIMITOTIC AGENT; BROMODEOXYCYTIDINE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLINE; CYTOTOXIC AGENT; ETOPOSIDE; LIPOCORTIN 5; PLANT EXTRACT; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D1; CYCLIN E; DOWN-REGULATION; G0 PHASE; G1 PHASE; HUMANS; LUNG NEOPLASMS; OLEANOLIC ACID; RETINOBLASTOMA PROTEIN;

EID: 79960457806     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Bayman NA, Sheikh H, Kularatne B, Lorigan P, Blackhall F, Thatcher N and Faivre-Finn C: Radiotherapy for small-cell lung cancer-Where are we heading? Lung Cancer 63: 307-314, 2009.
3. Saloustros E and Georgoulias V: Docetaxel in the treatment of advanced non-small cell lung cancer. Expert Rev Anticancer Ther 8: 1207-1222, 2008.
4. Yamamoto H, Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y and Tamura T: Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology 75: 169-174, 2008.
5. Newman DJ, Cragg GM and Snader KM: The influence of natural products upon drug discovery. Nat Prod Rep 17: 215-234, 2000.
6. Graham JG, Quinn ML, Fabricant DS and Farnsworth NR: Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol 73: 347-377, 2000.
7. Pezzuto JM: Plant-derived anticancer agents. Biochem Pharmacol 55: 121-133, 1997.
8. Ovesna Z, Vachalkova A, Horvathova K and Tathova D: Pentacyclic triterpenoic acids: new chemoprotective compounds. Neoplasma 51: 327-333, 2004. (Pubitemid 39486104)
9. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, Kenzaki K, Miyoshi T, Kondo K, Bando Y, Ohnishi Y and Tangoku A: Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer 125: 952-960, 2009.
10. Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G and Aggarwal BB: Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 5: 943-955, 2007. (Pubitemid 47416671)
11. Fernandes J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA and Gattass CR: Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug-resistant and -sensitive leukemia cell lines. Cancer Lett 190: 165-169, 2003. (Pubitemid 36136015)
12. Sun HX, Zheng QF and Tu J: Induction of apoptosis in HeLa cells by 3β-hydroxy-12-oleanen-27-oic acid from the rhizomes of Astilbe chinensis. Bioorg Med Chem 14: 1189-1198, 2006.
13. Van le TK, Hung TM, Thuong PT, Ngoc TM, Kim JC, Jang HS, Cai XF, Oh SR, Min BS, Woo MH, Choi JS, Lee HK and Bea K: Oleanane-type triterpenoids from Aceriphyllum rossii and their cytotoxic activity. J Nat Prod 72: 1419-1423, 2009.
14. Lee I, Yoo JK, Na M, Min BS, Lee J, Yun BS, Jin W, Kim H, Youn U, Chen QC, Song KS, Seong YH and Bae K: Cytotoxicity of triterpenes isolated from Aceriphyllum rossii. Chem Pharm Bull 55: 1376-1378, 2007.
15. Na M, Cui L, Min BS, Bae K, Yoo JK, Kim BY, Oh WK and Ahn JS: Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett 16: 3273-3276, 2006.
16. Min BS, Lee I, ChangMJ, Yoo JK, Na M, Hung TM, Thuong PT, Lee J, Kim JH, Kim JC, Woo MH, Choi JS, Lee HK and Bae K: Anticomplementary activity of triterpenoids from the whole plant of Aceriphyllum rossii against the classical pathway. Planta Med 74: 726-729, 2008.
17. Kim SS, Won SJ, Kim NJ, Yoo JK, Bae K and Lee KT: 3-Oxoolean-12-en-27-oic acid isolated from Aceriphyllum rossii induces caspase-8-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Bio Pharm Bull 32: 91-98, 2009.
18. Price P and McMillan TJ: Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res 50: 1392-1396, 1990. (Pubitemid 20090446)
19. Schwartz GK and Shah MA: Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol 23: 9408-9421, 2005.
20. Dickson MA and Schwartz GK: Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16: 36-43, 2009.
21. Gajra A, Newman N, Gamble GP, Abraham NZ, Kohman LJ and Graziano SL: Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer 42: 51-57, 2003. (Pubitemid 37153135)
22. Gali-Muhtasib H and Bakkar N: Modulating cell cycle: current applications and prospects for future drug development. Curr Cancer Drug Targets 2: 309-336, 2002. (Pubitemid 35303467)
23. Wong CF, Guminski A, Saunders NA and Burgess AJ: Exploiting novel cell cycle targets in the development of anticancer agents. Curr Cancer Drug Targets 5: 85-102, 2005. (Pubitemid 40488596)
24. Nabel EG: CDKs and CKIs: molecular targets for tissue remodelling. Nat Rev Drug Discov 1: 587-598, 2002.
25. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783, 2006.
26. 1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.